Development of the Ultra-Low Vision Visual Functioning Questionnaire (ULV-VFQ).

Pamela E Jeter, Collin Rozanski, Robert Massof, Olukemi Adeyemo, Gislin Dagnelie, and the PLOVR Study Group
Author Information
  1. Pamela E Jeter: Lions Vision Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  2. Collin Rozanski: Lions Vision Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  3. Robert Massof: Lions Vision Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  4. Olukemi Adeyemo: Lions Vision Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  5. Gislin Dagnelie: Lions Vision Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

PURPOSE: To develop and psychometrically evaluate a visual functioning questionnaire (VFQ) in an ultra-low vision (ULV) population.
METHODS: Questionnaire items, based on visual activities self-reported by a ULV population, were categorized by functional visual domain (e.g., mobility) and visual aspect (e.g., contrast) to ensure a representative distribution. In Round 1, an initial set of 149 items was generated and administered to 90 participants with ULV (visual acuity [VA] ≤ 20/500; mean [SD] age 61 [15] years), including six patients with a retinal implant. Psychometric properties were evaluated through Rasch analysis and a revised set (150 items) was administered to 80 participants in Round 2.
RESULTS: In Round 1, the person measure distribution (range, 8.6 logits) was centered at -1.50 logits relative to the item measures. In Round 2, the person measure distribution (range, 9.5 logits) was centered at -0.86 relative to the item mean. The reliability index in both rounds was 0.97 for Items and 0.99 for Persons. Infit analysis showed four underfit items in Round 1, five underfit items in Round 2 with a z-score greater than 4 cutoff. Principal component analysis on the residuals found 69.9% explained variance; the largest component in the unexplained variance was less than 3%.
CONCLUSIONS: The ULV-VFQ, developed with content generated from a ULV population, showed excellent psychometric properties as well as superior measurement validity in a ULV population.
TRANSLATIONAL RELEVANCE: The ULV-VFQ, part of the Prosthetic Low Vision Rehabilitation (PLoVR) development program, is a new VFQ developed for assessment of functional vision in ULV populations.

Keywords

References

  1. Invest Ophthalmol Vis Sci. 2004 Nov;45(11):3919-28 [PMID: 15505037]
  2. Arch Ophthalmol. 2001 Jul;119(7):1050-8 [PMID: 11448327]
  3. Clin Exp Ophthalmol. 2000 Jun;28(3):156-61 [PMID: 10981786]
  4. Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):198-204 [PMID: 17896298]
  5. Mol Ther. 2010 Mar;18(3):643-50 [PMID: 19953081]
  6. Optom Vis Sci. 2007 Aug;84(8):763-74 [PMID: 17700339]
  7. Transl Vis Sci Technol. 2017 May 31;6(3):12 [PMID: 28573076]
  8. Invest Ophthalmol Vis Sci. 1997 Jan;38(1):72-82 [PMID: 9008632]
  9. Eye (Lond). 2007 Oct;21(10):1352-9 [PMID: 17914439]
  10. Arch Phys Med Rehabil. 2005 May;86(5):954-67 [PMID: 15895342]
  11. Prog Brain Res. 2009;175:317-32 [PMID: 19660665]
  12. Optom Vis Sci. 2001 May;78(5):335-42 [PMID: 11384011]
  13. Arch Ophthalmol. 1994 Mar;112(3):329-35 [PMID: 8129657]
  14. J Rehabil Res Dev. 2004 Mar;41(2):233-41 [PMID: 15558377]
  15. Expert Rev Med Devices. 2014 Jan;11(1):23-30 [PMID: 24308734]
  16. Invest Ophthalmol Vis Sci. 2001 May;42(6):1215-25 [PMID: 11328730]
  17. Curr Opin Neurol. 2012 Feb;25(1):67-75 [PMID: 22185902]
  18. Ophthalmic Physiol Opt. 2004 Jul;24(4):257-73 [PMID: 15228503]
  19. Optom Vis Sci. 2012 Sep;89(9):1308-15 [PMID: 22902422]
  20. Am J Ophthalmol. 2000 Sep;130(3):350-2 [PMID: 11020415]
  21. Ophthalmic Epidemiol. 2011 Feb;18(1):1-19 [PMID: 21275592]
  22. Ophthalmic Epidemiol. 1998 Dec;5(4):185-210 [PMID: 9894804]
  23. Aust N Z J Ophthalmol. 1999 Jun-Aug;27(3-4):184-6 [PMID: 10484186]
  24. Int Ophthalmol Clin. 2003 Spring;43(2):17-30 [PMID: 12711900]
  25. Invest Ophthalmol Vis Sci. 2014 Sep 04;55(10):6150-8 [PMID: 25190656]
  26. Arch Phys Med Rehabil. 2005 May;86(5):946-53 [PMID: 15895341]
  27. Transl Res. 2014 Apr;163(4):377-86 [PMID: 24291154]
  28. Arch Ophthalmol. 2012 Aug;130(8):1028-37 [PMID: 22893074]
  29. Optom Vis Sci. 2007 Aug;84(8):675-82 [PMID: 17700332]
  30. Arch Ophthalmol. 1997 Nov;115(11):1447-55 [PMID: 9366678]
  31. Ophthalmic Epidemiol. 2004 Dec;11(5):381-99 [PMID: 15590585]
  32. Am J Med Qual. 2006 Jan-Feb;21(1):49-56 [PMID: 16401705]
  33. Expert Rev Med Devices. 2006 May;3(3):315-25 [PMID: 16681453]
  34. Optom Vis Sci. 2007 Aug;84(8):E690-705 [PMID: 17700325]
  35. Transl Res. 2013 Apr;161(4):241-54 [PMID: 23305707]
  36. J Neural Eng. 2009 Jun;6(3):035003 [PMID: 19458402]
  37. Transl Vis Sci Technol. 2013 Jun 25;2(3):1 [PMID: 24049716]
  38. Optom Vis Sci. 1995 Oct;72(10):725-36 [PMID: 8570162]
  39. Optom Vis Sci. 2013 Aug;90(8):720-44 [PMID: 23873034]
  40. Curr Genomics. 2011 Jun;12(4):276-84 [PMID: 22131873]
  41. Optom Vis Sci. 2007 Aug;84(8):663-74 [PMID: 17700331]
  42. Ophthalmology. 2012 Apr;119(4):779-88 [PMID: 22244176]
  43. Optom Vis Sci. 2012 Nov;89(11):1601-10 [PMID: 23069725]
  44. Patient. 2017 Feb;10 (1):39-49 [PMID: 27495171]
  45. Pharmacoeconomics. 2002;20(12):791-812 [PMID: 12236802]
  46. Ophthalmology. 2015 Aug;122(8):1547-54 [PMID: 26162233]
  47. Appl Opt. 1987 Apr 15;26(8):1468-72 [PMID: 20454345]
  48. Aust N Z J Ophthalmol. 1998 May;26 Suppl 1:S16-8 [PMID: 9685012]
  49. Am J Ophthalmol. 1999 Jul;128(1):45-53 [PMID: 10482093]
  50. Optom Vis Sci. 1998 May;75(5):349-73 [PMID: 9624700]
  51. Invest Ophthalmol Vis Sci. 2003 Sep;44(9):4131-9 [PMID: 12939337]
  52. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):927-35 [PMID: 11923230]
  53. Br J Ophthalmol. 2010 Jun;94(6):730-5 [PMID: 20508047]
  54. Clin Ophthalmol. 2014;8:127-36 [PMID: 24391438]

Grants

  1. R01 EY021220/NEI NIH HHS

Word Cloud

Created with Highcharts 10.0.0ULVRoundvisualitemsvisionpopulationanalysisfunctionaldistribution12logitsULV-VFQquestionnaireVFQQuestionnaireegsetgeneratedadministeredparticipantsmeanpropertiesRaschpersonmeasurerangecenteredrelativeitem0showedunderfitcomponentvariancedevelopedVisiondevelopmentVisualPURPOSE:developpsychometricallyevaluatefunctioningultra-lowMETHODS:basedactivitiesself-reportedcategorizeddomainmobilityaspectcontrastensurerepresentativeinitial14990acuity[VA]20/500[SD]age61[15]yearsincludingsixpatientsretinalimplantPsychometricevaluatedrevised15080RESULTS:86-150measures95-086reliabilityindexrounds97Items99PersonsInfitfourfivez-scoregreater4cutoffPrincipalresidualsfound699%explainedlargestunexplainedless3%CONCLUSIONS:contentexcellentpsychometricwellsuperiormeasurementvalidityTRANSLATIONALRELEVANCE:partProstheticLowRehabilitationPLoVRprogramnewassessmentpopulationsDevelopmentUltra-LowFunctioningAbilitypatient-reportedoutcomeultralowvision-relatedqualitylife

Similar Articles

Cited By